Navigation Links
NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD
Date:10/24/2011

LOS ANGELES, Oct. 24, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical technology company, announced today that it has signed a contract with the University of California, Los Angeles (UCLA) to fund a Phase I pediatric clinical trial to study the use of non-invasive, external Trigeminal Nerve Stimulation (TNS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).  NeuroSigma is the exclusive worldwide licensee of UCLA's TNS intellectual property.

This study will be an open-label clinical trial of external TNS (eTNS™) therapy in 10 subjects with ADHD. The study will enroll boys and girls between 9 and 14 years of age, marking the first study in which children may enroll in a TNS trial.

The principal investigator for this Phase I eTNS™ ADHD study is James McGough, M.D., M.S., Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior and David Geffen School of Medicine at UCLA. Dr. McGough also serves as director of clinical teaching programs in both Child and Adolescent Psychopharmacology and ADHD at UCLA.

"Intriguing findings from PET scan and clinical data in adults encouraged us to undertake this study of a promising alternative to medications and behavioral therapy," said Dr. McGough, who has contributed to the field's understanding of ADHD's causes and treatments for nearly two decades.  

"I'm excited that this new approach to neuromodulation may be able to have an impact on a broad range of neuropsychiatric disorders," said Ian Cook, M.D., one of the inventors of TNS and Director of the UCLA Depression Research & Clinic Program, where initial studies of TNS in depression and PTSD were started. Dr. Cook is also an advisor to NeuroSigma.

"This study is an important step forward in potentially broadening the clinical indications for TNS.  We are very pleased to be working with Dr. McGough who is widely regarded as a leader in ADHD
'/>"/>

SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeuroSigma, Inc. Retains CCG Investor Relations
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
4. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
5. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
6. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
7. Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees
8. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
9. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
10. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
11. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. ... SNY ; EURONEXT: SAN) and the life sciences ... to improve care and outcomes for people with type ... in diabetes treatments and devices with Google,s expertise in ... companies will explore how to improve diabetes care by ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... Chicago -based Rush University Medical ... activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor ... motor complete cervical spinal cord injury (SCI). This ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... in the New England ... and JACKSONVILLE, Fla., March 24 A study published ... Medicine suggests that intensive blood glucose (sugar) control ... does not improve outcomes and is associated with an ...
... 24 Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company ... of safety and efficacy data from the first cohort of ... recommended that Anthera,s Phase II clinical trial, known as the ... P hospholipase in A cute C hes ...
Cached Medicine Technology:Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 2Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 3Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 4Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3
(Date:8/31/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 , ... ... function and other clinically relevant measures for physical therapy patients. The Registry is being ... President of FOTO, Inc. stated "We are happy to be selected to contribute FOTO ...
(Date:8/31/2015)... ... 31, 2015 , ... Cosmetic Town Journal is an online ... have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients ... ready to help. , It is clear that the Cosmetic Town aesthetic surgery ...
(Date:8/31/2015)... ... ... to undergoing a hair transplant, most patients have donor hair moved from one part of ... on top of the scalp, as well as filling in areas missing hair, is a ... areas of their head. , What about patients who have a limited, or even depleted, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law firm ... Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... of attorneys in the state of Illinois. The nomination process is based on statewide ...
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based ... In this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate ... programs that have contributed to the company’s rapid growth. As the CareSource business ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
... a great way to stay physically active while enjoying ... that mountain biking-related injuries have decreased. A new study ... and Policy of The Research Institute at Nationwide Children,s ... 56 percent over the 14-year study period (1994 to ...
... 3 (HealthDay News) -- Daily electronic records of symptoms ... the condition, a new study shows. Researchers gave ... device. The patients used their PDA to report pain, ... a day for 30 days. The researchers at ...
... HealthDay Reporter , WEDNESDAY, Feb. 2 (HealthDay News) -- A large ... human papillomavirus (HPV) as well as it protects young women. ... also has been linked to penile cancer and other malignancies in ... of the New England Journal of Medicine , which was ...
... LOS ANGELES (Feb. 2, 2011) A team of scientists ... $1.9 million grant from the California Institute for Regenerative ... pharmaceutical discoveries for specific diseases. Additionally, another ... $1.5 million grant with a medical technology company aiming to ...
... spring will come on time, and NASA satellite data suggests ... now anxious for the prediction to come true. ... couple of days, including Phil,s home at Gobbler,s Knob in ... this morning before it changed to snow as part of ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Feb. ... new antibiotic for the increasingly common intestinal infection ... elderly, suggest it prevents recurrence far better than currently ... against vancomycin, a powerful drug often prescribed to ...
Cached Medicine News:Health News:New national study finds mountain bike-related injuries down 56 percent 2Health News:Gardasil Vaccine Guards Against HPV in Boys 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 3Health News:GOES-13 Satellite sees Groundhog's Day on ice 2Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 2Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 3
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: